{"id":"NCT01617447","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder","officialTitle":"A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2012-06-12","resultsPosted":"2017-04-11","lastUpdate":"2017-04-11"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Autistic Disorder"],"interventions":[{"type":"DRUG","name":"Placebo of Aripiprazole","otherNames":[]},{"type":"DRUG","name":"Aripiprazole","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder","primaryOutcome":{"measure":"Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score","timeFrame":"baseline, 8 weeks after dosing","effectByArm":[{"arm":"Aripiprazole","deltaMin":-11.4,"sd":1.3},{"arm":"Placebo","deltaMin":-7.5,"sd":1.4}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":["37811711"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Somnolence","Nasopharyngitis","Decreased appetite","Gastroenteritis","Nausea"]}}